<DOC>
	<DOCNO>NCT02219178</DOCNO>
	<brief_summary>This study aim evaluate overall response rate 4 cycle best response induction therapy combination lenalidomide , subcutaneous bortezomib , dexamethasone ( RsqVD ) patient newly diagnose multiple myeloma .</brief_summary>
	<brief_title>Study Efficacy Safety RsqVD Combination Therapy Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Participants must diagnosis symptomatic MM , accord International Myeloma Foundation 2003 Diagnostic Criteria : Clonal plasma cell &gt; 10 % bone marrow biopsy A monoclonal protein ( paraprotein ) either serum urine ( except case nonsecretory myeloma ) . If monoclonal protein detect ( nonsecretory disease ) , ≥ 30 % monoclonal bone marrow plasma cell and/or biopsyproven plasmacytoma require . Evidence endorgan damage felt related plasma cell disorder relate organ tissue impairment ( ROTI ) , commonly refer acronym 'CRAB ' : Hypercalcaemia : serum calcium ( correct albumin ) &gt; 10.5mg/sL/ &gt; 2.65mmol/L upper limit normal Renal insufficiency define serum creatinine &gt; 2mg/sL/177μmol/L Anaemia : Normochromic , normocytic haemoglobin value &gt; 2g/dL low limit normal haemoglobin &lt; 10g/dL Bone lesion ( lytic lesion , severe osteopenia pathologic fracture ) show CT scan and/or skeletal survey 2 . Patient receive prior treatment systemic therapy treatment multiple myeloma . Prior treatment hypercalcaemia spinal cord compression corticosteroid disqualify patient ( dose exceed equivalent 160 mg dexamethasone 2 week period ) Bisphosphonates permitted Patients treat local radiotherapy without concomitant exposure steroid , pain control management cord/nerve root compression , eligible . Two week must lapse since last date radiotherapy , recommend limited field . Patients require concurrent radiotherapy entry protocol defer radiotherapy complete 2 week pass since last date therapy . 3 . Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care 4 . Age ≥ 18 year time signing Informed Consent 5 . Females reproductive potential must adhere scheduled pregnancy test require Lenalidomide Pregnancy Prevention Risk Management Plan . Females childbearing potential ( FCBP ) must negative serum urine pregnancy test sensitivity least 50 mlU/mL 10 to14 day prior therapy repeat within 24 hour prior prescribe lenalidomide Cycle 1 ( prescription must fill within 7 day require Lenalidomide Pregnancy Prevention Risk Management Plan ) must either commit complete abstinence heterosexual contact begin TWO acceptable method birth control , one highly effective method one additional effective ( barrier ) method , AT THE SAME TIME , least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must practice complete abstinence agree use condom sexual contact FCBP even successful vasectomy . All study participant must register mandatory Lenalidomide Pregnancy Prevention Risk Management Plan , willing able comply requirement Lenalidomide Pregnancy Prevention Risk Management Plan . *A female childbearing potential sexually mature female : 1 ) undergone hysterectomy ( surgical removal uterus ) bilateral oophorectomy ( surgical removal ovary ) 2 ) naturally postmenopausal ( amenorrhea follow cancer therapy rule childbearing potential ) least 24 consecutive month ( i.e . menses time precede 24 consecutive month ) 6 . All necessary baseline study determine eligibility must obtain within 21 day prior enrolment 7 . Subject ECOG performance status &lt; 2 Karnofsky performance status ≥ 60 ( Appendix E ) . 8 . Subject must able adhere study visit schedule protocol requirement . 1 . Patient ≥ Grade 2 peripheral neuropathy clinical examination within 14 day enrolment 2 . Renal insufficiency ( serum creatinine level &gt; 2.5 mg/dL/221μmol/L , calculate creatinine clearance CockcroftGault formula ( see Appendix G ) &lt; 45 ml/min ) 3 . Subjects evidence mucosal internal bleeding and/or platelet refractory ( i.e . unable maintain platelet count 50,000 cells/mm3 ) 4 . Subjects absolute neutrophil count ( ANC ) &lt; 1000 cells/mm3 . Growth factor may use meet ANC eligibility criterion 5 . Subjects haemoglobin &lt; 8.0 g/dL 6 . AST ( SGOT ) ALT ( SGPT ) &gt; 2 x ULN , bilirubin level 1.5 ULN 7 . Concomitant therapy medication include corticosteroid ( except indicate inclusion criterion ) 8 . Myocardial infarction within 6 month prior enrolment New York Heart Association ( NYHA ) Class III IV heart failure ( Appendix G ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormalities 9 . Clinically relevant active infection require treatment ( antibiotic , antiviral , antifungal ) 10 . Any serious comorbid condition , include laboratory abnormality , opinion Investigator place subject unacceptable risk he/she participate study . 11 . Female subject pregnant breastfeeding 12 . Serious psychiatric illness addiction likely interfere participation clinical study 13 . Uncontrolled diabetes mellitus 14 . Contraindication require concomitant drug supportive therapy include hypersensitivity anticoagulation antiplatelet option hypersensitivity acyclovir similar antiviral drug . History allergic reaction/hypersensitivity attribute compound contain boron , mannitol , polysorbate 80 sodium citrate dehydrate 15 . POEMS syndrome ( plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , monoclonal protein ( Mprotein ) skin change ) 16 . Known seropositive active HIV infection active hepatitis B C viral infection . Patients seropositive hepatitis B virus vaccine eligible 17 . Known intolerance steroid therapy 18 . Patient hypersensitivity bortezomib , boron , mannitol 19 . Diagnosed treat another malignancy within 2 year enrolment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy 20 . Participation clinical trial antimyeloma investigational agent include trial , within 14 day start trial throughout duration trial 21 . Radiation therapy within 2 week randomization . Enrolment subject require concurrent radiotherapy ( must localize field size ) defer radiotherapy complete 2 week elapse since last date therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>